

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OCR-1101

Applicant:	John A. Peyman
Filing date	June 7, 2001
Title of Application	Interferon-Suppressing Placental Lactogen Peptides


Box Sequence
Commissioner of Patents
and Trademarks
Washington, DC 20231

**SUBMISSION OF COMPUTER
READABLE COPY OF SEQUENCE LISTING**

Dear Sir:

Submitted herewith is a computer readable copy on a 3.5" 1.44 Mb diskette of the Sequence Listings for the sequences in the above-identified application, with each listing assigned a separate identifier as set forth in the application. Each submitted sequence listed herein and each computer readable copy on the enclosed diskette are the same

Respectfully submitted,




June 7, 2001

John A. Peyman, Ph.D.
336 West Rock Avenue
New Haven, CT 06515
(203) 974-6292

I hereby certify that this correspondence is today being deposited with the U.S. Postal Service as Express Mail No ET327960937US US in an envelope addressed to Box Sequence, Commissioner of Patents and Trademarks, Washington, DC 20231.

June 7, 2001



John A. Peyman

SEQUENCE LISTING

<110> Peyman, John A.

<120> Interferon-Suppressing Placental Lactogen Peptides

<130> 1101

<141> 2001-06-07

<150> 60/210,082

<151> 2000-06-07

<160> 16

<170> MS-DOS

<210> 1

<211> 789

<212> DNA

<213> HOMO SAPIENS

<220>

<222>

<223> hPL(1-28) cDNA

<400> 1

```

ctgtggacag ctcacctagc ggcaatggct gcaggctccc ggacgtccct   50
gctcctgggt tttgccctgc tctgcctgcc ctggcttcaa gaggctgggtg  100
ccgtccaaac cgttccgtta tccaggcttt ttgaccacgc tatgctccaa  150
gcccatcgcg cgcaccagct ggccattgac acctactagg agtttgaaga  200
aacctatatc ccaaaggacc agaagtattc attcctgcat gactcccaga  250
cctccttctg cttctcagac tctattccga caccctccaa catggaggaa  300
acgcaacaga aatccaatct agagctgctc cgcatctccc tgctgctcat  350
cgaatcgtag ctggagcccg tgcggttctt caggaatatg ttcgccaaca  400
acctggtgta tgacacctcg gacagcgatg actatcacct cctaaaggac  450
ctagaggaag gcatccaaac gctgatgggg aggctggaag acggcagccg  500
ccggactggg cagatcctca agcagaccta cagcaagttt gacacaaact  550
cgcacaacca tgacgcactg ctcaagaact acgggctgct ctactgcttc  600

```

```

aggaaggaca tggacaaggt cgagacattc ctgcgcatgg tgcagtgccg 650
ctctgtggag ggcagctgtg gcttctaggt gcccgcgtgg catcctgtga 700
ccgacccctc cccagtgcct ctctggccc ctggaaggtg ccactcagtg 750
cccatcagcc ttgtcctaataaaaattaagt tgtatcatc 789

```

<210> 2

<211> 54

<212> PRT

<213> HOMO SAPIENS

<220>

<223> hPL(1-28) signal sequence and secreted peptide, or N-terminal 54 residues of hPL-3

<400> 2

```

Met Ala Ala Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Ala Leu
      5                      10                      15
Leu Cys Leu Pro Trp Leu Gln Glu Ala Gly Ala Val Gln Thr Val
      20                      25                      30
Pro Leu Ser Arg Leu Phe Asp His Ala Met Leu Gln Ala His Arg
      35                      40                      45
Ala His Gln Leu Ala Ile Asp Thr Tyr
      50

```

<210> 3

<211> 54

<212> PRT

<213> HOMO SAPIENS

<220>

<223> N-terminal 54 residues of hPL-4

<400> 3

```

Met Ala Pro Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Ala Leu
      5                      10                      15
Leu Cys Leu Pro Trp Leu Gln Glu Ala Gly Ala Val Gln Thr Val
      20                      25                      30
Pro Leu Ser Arg Leu Phe Asp His Ala Met Leu Gln Ala His Arg
      35                      40                      45

```

Ala His Gln Leu Ala Ile Asp Thr Tyr
50

<210> 4

<211> 28

<212> PRT

<213> HOMO SAPIENS

<220>

<223> hPL(1-28) peptide

<400> 4

Val Gln Thr Val Pro Leu Ser Arg Leu Phe Lys Glu Ala Met Leu
5 10 15

Gln Ala His Arg Ala His Gln Leu Ala Ile Asp Thr Tyr
20 25

<210> 5

<211> 162

<212> DNA

<213> HOMO SAPIENS

<220>

<223> cDNA construct coding for signal sequence and secreted peptide of hPL(1-28)

<400> 5

atggctccag gctcccgac gtcctgctc ctggcttttg cctgctctg 50
cctgccctgg cttcaagagg ctggtgccgt ccaaaccgtt ccgttatcca 100
ggctttttga ccacgctatg ctccaagccc atcgcgcgca ccagctggcc 150
attgacacct ac 162

<210> 6

<211> 54

<212> PRT

<213> HOMO SAPIENS

<220>

<223> N-terminal 54 residues of hPL-4

<400> 6

```
Met Ala Ala Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Ala Leu
      5                      10                      15
Leu Cys Leu Pro Trp Leu Gln Glu Ala Gly Ala Val Gln Thr Val
      20                      25                      30
Pro Leu Ser Arg Leu Phe Lys Glu Ala Met Leu Gln Ala His Arg
      35                      40                      45
Ala His Gln Leu Ala Ile Asp Thr Tyr
      50
```

<210> 7

<211> 28

<212> PRT

<213> HOMO SAPIENS

<220>

<223> hPL-1(1-28) peptide

<400> 7

```
Val Gln Thr Val Pro Leu Ser Arg Leu Phe Lys Glu Ala Met Leu
      5                      10                      15
Gln Ala His Arg Ala His Gln Leu Ala Ile Asp Thr Tyr
      20                      25
```

<210> 8

<211> 162

<212> DNA

<213> HOMO SAPIENS

<220>

<223> cDNA construct coding for signal sequence and secreted peptide of hPL-1(1-28)

<400> 8

```
atggctgcag gctcccgac gtcctgctc ctggcttttg cctgctctg 50
cctgcctgg cttcaagagg ctggtgccgt ccaaccgtt cccttatcca 100
ggctttttta agaggctatgc tccaagccc atcgcgacaca ccagctggcc 150
attgacacct ac 162
```

<210> 9

<211> 87

<212> DNA

<213> HOMO SAPIENS

<220>

<223> hPL(1-28) 87-mer oligo

<400> 9

atggctccag gctcccgac gtccctgtc ctggcttttg ccctgctctg 50

cctgccctgg cttcaagagg ctggtgccgt ccaaacc 87

<210> 10

<211> 85

<212> DNA

<213> HOMO SAPIENS

<220>

<223> hPL(1-28) 85-mer oligo

<400> 10

gtaggtgtca atggccagct ggtgcgcgcg atgggcttgg agcatagcgt 50

ggtcaaaaag cctggataac ggaacggttt ggacg 85

<210> 11

<211> 85

<212> DNA

<213> HOMO SAPIENS

<220>

<223> hPL-1(1-28) 85-mer oligo

<400> 11

gtaggtgtca atggccagct ggtgtgcgcg atgggcttgg agcatagcct 50

ctttaaaaag cctggataag ggaacggttt ggacg 85

<210> 12

<211> 24

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> pSH4-1

<400> 12

gatgttgccctt tacttctag gcct

24

<210> 13

<211> 24

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> pSH4-2

<400> 13

aactcatcaa tgtatcttat catg

24

<210> 14

<211> 54

<212> PRT

<213> HOMO SAPIENS

<220>

<223> N-TERMINAL 54 RESIDUES OF HGH-1

<400> 14

Met Ala Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly Leu
5 10 15

Leu Cys Leu Pro Trp Leu Gln Glu Gly Ser Ala Phe Pro Thr Ile
20 25 30

Pro Leu Ser Arg Leu Phe Asp Asn Ala Ser Leu Arg Ala His Arg
35 40 45

Leu His Gln Leu Ala Phe Asp Thr Tyr
50

<210> 15

<211> 56

<212> PRT

<213> HOMO SAPIENS

<220>

<223> N-TERMINAL 56 RESIDUES OF HGH-V

<400> 15

Met	Ala	Ala	Gly	Ser	Arg	Thr	Ser	Leu	Leu	Leu	Ala	Phe	Gly	Leu	
				5					10					15	
Leu	Cys	Leu	Ser	Trp	Leu	Gln	Glu	Gly	Ser	Ala	Phe	Pro	Thr	Ile	
				20					25					30	
Pro	Leu	Ser	Arg	Leu	Phe	Asp	Asn	Ala	Ser	Leu	Arg	Ala	Arg	Asp	
				35					40					45	
Leu	Phe	Asp	Arg	Ala	Val	Val	Leu	Ser	His	Tyr					
				50					55						

<210> 16

<211> 56

<212> PRT

<213> HOMO SAPIENS

<220>

<223> N-TERMINAL 56 RESIDUES OF HPRL

<400> 16

Met	Asn	Ile	Lys	Gly	Ser	Pro	Trp	Lys	Gly	Ser	Leu	Leu	Leu	Leu	
				5					10					15	
Leu	Val	Ser	Asn	Leu	Leu	Leu	Cys	Gln	Ser	Val	Ala	Pro	Leu	Pro	
				20					25					30	
Ile	Cys	Pro	Gly	Gly	Ala	Ala	Arg	Cys	Gln	Val	Thr	Leu	Arg	Asp	
				35					40					45	
Leu	Phe	Asp	Arg	Ala	Val	Val	Leu	Ser	His	Tyr					
				50					55						